Editorial Board
(Source: Drug Resistance Updates)
Source: Drug Resistance Updates - March 1, 2015 Category: Drugs & Pharmacology Source Type: research
RhoGTPases – A novel link between cytoskeleton organization and cisplatin resistance
For more than three decades, platinum compounds have been the first line treatment for a wide spectrum of solid tumors. Yet, cisplatin resistance is a major impediment in cancer therapy, and deciphering the mechanisms underlying chemoresistance is crucial for the development of novel therapies with enhanced efficacy. The Rho subfamily of small GTPases plays a significant role in cancer progression, and a growing body of evidence points toward the involvement of these proteins in anticancer drug resistance, including cisplatin resistance. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - January 22, 2015 Category: Drugs & Pharmacology Authors: Daphna Mokady, David Meiri Source Type: research
RhoGTPases - a novel link between cytoskeleton organization and cisplatin resistance
For more than three decades, platinum compounds have been the first line treatment for a wide spectrum of solid tumors. Yet, cisplatin resistance is a major impediment in cancer therapy, and deciphering the mechanisms underlying chemoresistance is crucial for the development of novel therapies with enhanced efficacy. The Rho subfamily of small GTPases plays a significant role in cancer progression, and a growing body of evidence points toward the involvement of these proteins in anticancer drug resistance, including cisplatin resistance. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - January 22, 2015 Category: Drugs & Pharmacology Authors: Daphna Mokady, David Meiri Source Type: research
Editorial Board
(Source: Drug Resistance Updates)
Source: Drug Resistance Updates - January 1, 2015 Category: Drugs & Pharmacology Source Type: research
Host effects contributing to cancer therapy resistance
There are several approaches for the management of malignant disease. However, tumor resistance to therapy is still a major challenge in the clinic. Efflux transporters, genetic responses and enzyme activity in tumor cells are examples of the main modalities that account for resistance to therapy. In addition, emerging evidence suggests that the host also plays a significant role in promoting therapy resistance. Recruitment of different host cell types to the treated tumor site occurs in response to a range of therapies, including chemotherapy, radiation, surgery and even targeted drugs. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - December 26, 2014 Category: Drugs & Pharmacology Authors: Ofrat Beyar Katz, Yuval Shaked Source Type: research
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy derived from ATP hydrolysis essentially to translocate, among various substrates, toxic compounds across the membrane. The fundamental functions of these multiple transporter proteins include: 1) conserved mechanisms related to nutrition and pathogenesis in bacteria; 2) spore formation in fungi, and 3) signal transduction, protein secretion and antigen presentation in eukaryotes. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - December 11, 2014 Category: Drugs & Pharmacology Authors: Rishil J. Kathawala, Pranav Gupta, Charles R. Ashby, Zhe-Sheng Chen Source Type: research
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia. However, the therapeutic efficacy of bortezomib is hampered by the emergence of acquired resistance, for which multifactorial mechanisms have been identified. This review summarizes the current status of the molecular mechanisms underlying resistance to proteasome inhibitors that emerged in preclinical therapeutic studies, and discusses these findings in t...
Source: Drug Resistance Updates - December 11, 2014 Category: Drugs & Pharmacology Authors: Denise Niewerth, Gerrit Jansen, Yehuda G. Assaraf, Sonja Zweegman, Gertjan L. Kaspers, Jacqueline Cloos Source Type: research
Antibody-targeted drugs and drug resistance—Challenges and solutions
Antibody-based therapy of various human malignancies has shown efficacy in the past 30 years and is now one of the most successful and leading strategies for targeted treatment of patients harboring hematological malignancies and solid tumors. Antibody–drug conjugates (ADCs) aim to take advantage of the affinity and specificity of monoclonal antibodies (mAbs) to selectively deliver potent cytotoxic drugs to antigen-expressing tumor cells. Key parameters for ADC include choosing the optimal components of the ADC (the antibody, the linker and the cytotoxic drug) and selecting the suitable cell-surface target antigen. (Sour...
Source: Drug Resistance Updates - November 21, 2014 Category: Drugs & Pharmacology Authors: LeeRon Shefet-Carasso, Itai Benhar Source Type: research
Antibody-targeted drugs and drug resistance - challenges and solutions
Antibody-based therapy of various human malignancies has shown efficacy in the past 30 years and is now one of the most successful and leading strategies for targeted treatment of patients harboring hematological malignancies and solid tumors. Antibody-drug conjugates (ADCs) aim to take advantage of the affinity and specificity of monoclonal antibodies (mAbs) to selectively deliver potent cytotoxic drugs to antigen-expressing tumor cells. Key parameters for ADC include choosing the optimal components of the ADC (the antibody, the linker and the cytotoxic drug) and selecting the suitable cell-surface target antigen. (Source...
Source: Drug Resistance Updates - November 21, 2014 Category: Drugs & Pharmacology Authors: LeeRon Shefet-Carasso, Itai Benhar Source Type: research
The conserved multigene family of malaria parasites: Essential roles in host–pathogen interaction
The clag multigene family is strictly conserved in malaria parasites, but absent from neighboring genera of protozoan parasites. Early research pointed to roles in merozoite invasion and infected cell cytoadherence, but more recent studies have implicated channel-mediated uptake of ions and nutrients from host plasma. Here, we review the current understanding of this gene family, which appears to be central to host–parasite interactions and an important therapeutic target. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - November 3, 2014 Category: Drugs & Pharmacology Authors: Ankit Gupta, Girija Thiruvengadam, Sanjay A. Desai Source Type: research
The conserved multigene family of malaria parasites: essential roles in host-pathogen interaction
The clag multigene family is strictly conserved in malaria parasites, but absent from neighboring genera of protozoan parasites. Early research pointed to roles in merozoite invasion and infected cell cytoadherence, but more recent studies have implicated channel-mediated uptake of ions and nutrients from host plasma. Here, we review the current understanding of this gene family, which appears to be central to host-parasite interactions and an important therapeutic target. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - November 3, 2014 Category: Drugs & Pharmacology Authors: Ankit Gupta, Girija Thiruvengadam, Sanjay A. Desai Source Type: research
The folate receptor as a rational therapeutic target for personalized cancer treatment
Conventional cancer treatment modalities have several limitations including lack of sufficient efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In contrast, targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells, thus allowing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic. The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial,...
Source: Drug Resistance Updates - October 8, 2014 Category: Drugs & Pharmacology Authors: Yehuda G. Assaraf, Christopher P. Leamon, Joseph Reddy Source Type: research
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms
VEGF-targeted therapy is currently the first line treatment for patients with metastatic clear cell renal cell carcinoma (ccRCC), but most patients either display primary (intrinsic) resistance or acquire drug resistance. In recent years multiple mechanisms of resistance to VEGF-targeted therapy emerged from preclinical research, but it is currently unknown to what extent these drug resistance modalities play a role in the clinic. Here we reviewed the current literature on biomarkers that predict treatment outcome in patients with ccRCC to gain insight in clinical drug resistance mechanisms. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - October 7, 2014 Category: Drugs & Pharmacology Authors: Johannes C. van der Mijn, James W. Mier, H.J. Broxterman, Henk M. Verheul Source Type: research
On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data
Multidrug resistant tuberculosis (MDR-TB) poses serious challenges for tuberculosis control in many settings, but trends of MDR-TB have been difficult to measure. (Source: Drug Resistance Updates)
Source: Drug Resistance Updates - October 6, 2014 Category: Drugs & Pharmacology Authors: Ted Cohen, Helen E. Jenkins, Chunling Lu, Megan McLaughlin, Katherine Floyd, Matteo Zignol Source Type: research
Editorial Board
(Source: Drug Resistance Updates)
Source: Drug Resistance Updates - October 1, 2014 Category: Drugs & Pharmacology Source Type: research
